Brief: FDA Approves Vimseltinib For Symptomatic Tenosynovial Giant Cell Tumor
14/02/2025 20:51
Feb 14 (Reuters) - U.S. FDA:
* FDA APPROVES VIMSELTINIB FOR SYMPTOMATIC TENOSYNOVIAL
GIANT CELL
TUMOR
* U.S. FDA: ROMVIMZA APPROVED FOR ADULT PATIENTS WITH
SYMPTOMATIC
TENOSYNOVIAL GIANT CELL TUMOR
Further company coverage: 4528.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ONO PHARMACEUTICAL
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours